173.59 0.00 (0.00%)
After hours: 6:10PM EDT
|Bid||173.75 x 800|
|Ask||175.00 x 800|
|Day's Range||172.32 - 175.16|
|52 Week Range||151.80 - 195.81|
|Beta (3Y Monthly)||1.03|
|PE Ratio (TTM)||20.37|
|Earnings Date||Oct 22, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||216.21|
Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Companies with outsize growth prospects aren't hard to find. High-growth stocks that also are high on quality are another matter.Seemingly every other week, a so-called unicorn files for an initial public offering. And yet more often than not, the stocks of these red-hot companies quickly disappoint investors. There's no point in betting on companies with high growth prospects if they don't have the quality to churn out such returns year after year.When it comes to looking for high-quality companies, a good place to start is with return on equity. ROE measures how adept a company is at squeezing a return out of its net assets. It's often used as a shorthand for quality. Although ROE differs from industry to industry, a rule of thumb is that ROE should come to at least 15%.Quality stocks can't be found by applying just a single measure, however. Balance sheets, fundamental performance and cash flow are critical too. As such, we scoured the Russell 1000 Growth Index of large- and midsize companies to find stocks with returns on equity of at least 15%. Additionally, these companies had to have positive free cash flow (FCF), healthy balance sheets and long-term growth rates of at least 20%.Lastly, they had to have an average analyst score of less than 2.0 from S&P; Global Market Intelligence. Any score below 2.0 equals a Buy recommendation on the part of Wall Street, and the lower the score, the better.Here, then, are the 10 best-rated high-quality, high-growth stocks to buy. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
[Editor's note: "Check Out These 5 Fast-Growing Stocks to Buy " was previously published in June 2019. It has since been updated to include the most relevant information available.]The benefit of fast-growing stocks is self-evident, but if inflation becomes something to start worrying about, fast-growing stocks have an importance tied to timing.Source: Shutterstock If inflation returns, growth will be more uneven than it has been in the past. At that point, you'll need to find firms with solid sales earnings growth as well as technical and fundamental strengths to keep the profits rolling.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? These are five fast-growing stocks to buy today that will keep you in good stead for years to come, even if inflation returns. Sherwin-Williams (SHW)Sherwin-Williams Co (NYSE:SHW) has sold paint and coatings now for 152 years. That's a pretty impressive record. But it's a bit unusual to see a paint company in a list of top growth stocks. Usually, it's some cloud-storage firm or a breakout online retailer.Source: Shutterstock However, SHW, by its size and reputation, has not only endured but it has positioned itself on top of the coatings heap. It grew from annual sales of $400,000 in 1866 to annual sales topping $15 billion last year, coming from over 100 countries around the world.Its size, scope and quality is one reason hardware giant Lowe's Companies, Inc. (NYSE:LOW) inked a deal to be the only nationwide home seller to offer SHW products. This is even more exciting given that housing demand is back on track and the interest in homeowners to fixing up their current houses. SHW is rated a "B" in my Portfolio Grader system. Vertex (VRTX)Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the leading pharmaceutical firms when it comes to treating cystic fibrosis (CF).Source: Shutterstock That may not seem like much of a franchise given all the other more compelling diseases out there, but VRTX has built a $43.8 billion market cap in the sector and most of its competitors are looking for other places to find an opening.That is a big deal for pharma companies that usually are strong until patents run down or generics start eating into margins. * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? Not so with VRTX. As new approvals keep rolling in for next-generation CF drugs, it has plenty more in the pipeline to keep this growth going. Royal Dutch Shell (RDS.A)Royal Dutch Shell (NYSE:RDS.A, NYSE:RDS.B) is one of the biggest players in the global energy markets. With a $227 billion market cap, the only Big Oil name that's bigger is Exxon Mobil (NYSE:XOM). It's what is called an integrated energy company because it has operations from the fields to the pipelines to the refineries to the distribution.Source: Mike Mozart via FlickrAs with all energy firms, when times are bad, the more exposure you have to the entire production and distribution process, the tougher things get. But at the size the big oils are, they have the money to wait out the bad patches.And that's just what RDS.A has done. Now it's time to cash in. RDS stock is rated a "C" by Portfolio Grader, but it is still delivering a mouth-watering 6.64% dividend. However, that may wane as the stock price starts rising. In the meanwhile, it's easy to see why this is one of our picks for the best fast-growing stocks. Lumentum (LITE)Lumentum Holdings Inc (NASDAQ: LITE) is a specialty company that focuses on laser beams. It's one of the biggest optical and photonics companies in the world that is working on the 3D sensing sector.Source: Shutterstock Essentially, 3D sensing is basically the gesture sensing that we all have become accustomed with in our mobile devices, screens in our cars, etc. It is one of the most ubiquitous aspects of our interactive age and one of the key parts of the Internet of Things (IoT) concept. * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? LITE stock's broader tailwinds make it worthwhile. That is to say, Lumentum is also a major player in the optical networking space that makes the infrastructure that makes our world "smarter," operating in as close to real time as possible. It's crucial for the next generation of cloud computing and network operations.Its laser division helps build the next generation of equipment that makes all this possible. Knight-Swift (KNX)Knight-Swift Transportation Holdings Inc (NYSE:KNX) had its humble beginnings in 1966, taking steel from the Port of Los Angeles to Arizona and bringing cotton from Arizona to LA. Today, KNX is a $6 billion business with 20,000 trucks on the road throughout the U.S. and Mexico. If you see a Swift logo on a truck while driving, it's a KNX truck.Source: David Guo via FlickrCharles Dow, the inspiration for the Dow Jones Industrial Average, also inspired a fundamental theory about the economy and the markets. It's simply called Dow Theory.One of the core tenants is that if you look at the transportation and the industrial sectors, you can predict how well the economy will be doing in the near future. If the transport business is rising, that's a bullish sign that the economy is on an upswing and KNX stock with it.It's worth mentioning, however, that KNX stock sports an "F" rating in my Portfolio Grader system on a quantitative basis, but it has a "C" rating for fundamentals. Its inclusion in this list lies with its astronomical growth -- KNX stock is up 41% from its January low, and its one-year price target of $42 represents 20% growth. On an earnings basis, Knight-Swift is predicted to grow earnings at a long-term (5-year) rate of 10%.Louis Navellier is a renowned growth investor. He is the editor of five investing newsletters: Blue Chip Growth, Emerging Growth, Ultimate Growth, Family Trust and Platinum Growth. His most popular service, Blue Chip Growth, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Best ETFs for 2019: The Race Is a Little More Gnarly Now * 7 Next-Generation Healthcare Stocks to Buy * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? The post Check Out These 5 Fast-Growing Stocks to Buy appeared first on InvestorPlace.
It’s the latest example of biotechs leaving Cambridge after being squeezed out of the white-hot life-sciences mecca that is Kendall Square.
A Durham-based company has landed a massive drug development deal following a successful fundraising series, bringing close to $28 million into the company now, and potentially $700 million down the road. Ribometrix, which is working to build a drug screening platform and develop small-molecule therapeutics that target RNA, has been developing in Durham's Biolab space since 2017 on $7.5 million in seed funding. The company also moved into a new headquarters in Durham.
Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that Carmen Bozic, M.D., has been appointed as the company’s Executive Vice President, Global Medicines Development and Medical Affairs. Dr. Bozic will assume the additional role of Chief Medical Officer on April 1, 2020 when Reshma Kewalramani, M.D., the company’s current Chief Medical Officer, becomes President and Chief Executive Officer of Vertex.
The scientific founder and CEO of Cambridge startup Dyne Therapeutics has hired a new CEO — a former CFO with experience in public stock offerings. Dyne’s current CEO, Romesh Subramanian, will be replaced by Joshua Brumm, who is leaving his post as CFO of Lexington microbiome startup Kaleido Biosciences and who has taken a California startup public.
While the S&P 500 is up nearly 19% heading into the final quarter of the year, biotech stocks are badly lagging the market, punishing the performance of many ETFs and other funds holding shares of companies such as Biogen (BIIB), Regeneron Pharmaceuticals Inc. (REGN), BioMarin Pharmaceutical Inc. (BMRN), Gilead Sciences Inc. (GILD), Vertex Pharmaceuticals Inc. (VRTX), and Alexion Pharmaceuticals Inc. (ALXN). The increasingly bearish sentiment is reflected in six consecutive weeks of outflows from biotech funds, amounting to about $2.1 billion, and marking the longest stretch of continuous outflows in nearly two years, as outlined by Barron’s. Weakness in the biotech sector has caused a long list of ETFs to fall sharply from their highs in the last few months, including the giant iShares Nasdaq Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and Invesco Dynamic Biotechnology & Genome ETF (PBE), just to name a few.
Vertex Pharmaceuticals Incorporated (VRTX) and RNA therapeutics developer Ribometrix, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix’s proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional (3D) RNA structures with Vertex’s scientific, clinical and regulatory capabilities for up to three therapeutic programs, including one ongoing discovery program from Ribometrix.
The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...